Sök artiklar i SveMed+


Status og perspektiver for behandling af de kroniske myeloproliferative neoplasier
Engelsk titel: Status and perspectives on chronic myeloproliferative neoplasm treatment Läs online Författare: Ocias, Lukas Frans ; Holmström, Morten Orebo ; Riley, Caroline Hasselbalch ; Lykkegaard Andersen, Christen ; Rönnov-Jessen, Dorte ; Starklint, Jörn ; Frederiksen, Mikael ; Saabye Steffensen, Morten ; Bjerrum, Ole Weis ; Farmer, Sarah ; Mourits-Andersen, Torben ; Hasselbalch, Hans Carl ; Stauffer Larsen, Thomas Språk: Dan Antal referenser: 30 Dokumenttyp: Översikt UI-nummer: 16037126

Tidskrift

Ugeskrift for Laeger 2015;177(26)2522-6 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Polycythaemia vera, essential thrombocytosis and primary myelofibrosis are closely related, clonal myeloproliferative neoplasms. Our knowledge of the underlying molecular mechanisms driving these diseases has increased dramatically during the latest ten years. Traditionally, treatment of these malignancies has focused on lowering their inherent thromboembolic risk but with the discovery of the JAK2-V617F mutation and most recently the calreticulin mutations new therapeutic options such as interferon-alpha, JAK2-inhibitors and statins are being contemplated. This article reviews these new treatment options.